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Abstract
Background: Mycobacterium tuberculosis (M. tb) that causes pulmonary tuberculosis
(PTB) occupies the lungs, while human β-defensin-1 (hBD1) is expressed in all human
epithelial tissues as one of the products of phagocytic leucocytes, especially at
the site of microbial colonisation such as the lungs. The involvement of hBD1 in
mycobacterial infection has not been extensively studied, thus there is the need
to measure the levels of the hBD1 in mononuclear cell lysates and sputum of PTB
patients at diagnosis. Materials and Methods: Ninety participants aged between 15
and 64 years were recruited as follows: 30 newly diagnosed multi-drug-resistant TB
(MDR-TB) patients and 30 newly diagnosed drug-sensitive TB patients (DS-TB) from
MDR-TB Treatment centre and the Medicine Outpatient Clinic at University College
Hospital (UCH) Ibadan, Nigeria. Thirty (30) non-TB apparently healthy individuals
served as controls. The analytical method employed for the measurement of hBD1
in the sputum and lysate was the Enzyme-linked immunosorbent assay (ELISA).
The data were expressed as mean and standard deviation, and the differences
between the means were established using Student (t) test. P-value ≤ 0.05 indicated
statistical significance. Results: The mean levels of lysate and sputum hBD1 were not
significantly different in newly diagnosed DS–TB patients (D0)compared with control
(p > 0.05). Whereas, the mean levels of lysate and sputum hBD1 were significantly
higher in newly diagnosed MDR–TB patients (M0) compared with newly diagnosed
DS–TB patients (D0)or control (p < 0.05). Conclusion: Due to the higher levels of
hBD1 in the sputum and lysate of M0 than in D0, one might conclude that there is
a relationship between chronicity of PTB and hBD1 level.
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1. Introduction
Tuberculosis (TB) is an infectious disease caused in humans by several strains of
mycobacterium, especially Mycobacterium tuberculosis (M. tb) [1]. Globally, TB has
remained a major health problem that is endemic in most developing countries of the
world and responsible for ill health among millions of people. Nigeria is ranked fourth
among the 22 countries with a high burden of TB in the world with a prevalence of
330 per 100,000 [2]. There is also an increasing incident of MDR-TB in Nigeria which is
jeopardising the efforts of TB control [2]. Among reasons why M. tb is a major health
problem globally is due to the occurrence of drug resistant strains of M. tb [3].
Resistance to TB drugs could result from inappropriate treatment with a single anti-
TB drug (usually isoniazid), wrong-drug prescription leading to ineffective treatment
and may also be due to the patient not taking the medication correctly, which can be
due to a variety of reasons, including cost or scarcity of medicines, patient’s forgetful-
ness, or patient stopping treatment early because they feel better [4]. None of these
reasons addressed innate intracellular components of cells involved in combating M.
tb infection.
Transmission of M. tb is via inhaled air and as M. tb reaches the pulmonary alveoli,
phagocytosis by alveolar macrophages and dendritic cells (DCs) is the first event in the
non-specific host–pathogen interaction [5, 6]. Alveolar macrophages and DCs recog-
nize M. tb through pattern recognition receptors (PRRs), such as pathogen-associated
molecular patterns (PAMPs), which trigger an intracellular signalling cascade in the
alveolar macrophages, leading to phagocytic activity [7, 8].
Anti-microbial peptides (AMPs), which include defensins, have been identified as
key elements in the innate host defence against infections [9]. Defensins possesses
and exerts antimicrobial and cytotoxic activities against microorganisms especially
during mycobacterium infection [10]. Apart from their antimicrobial abilities, defensins
also act as chemo-attractants to immature DCs and T cells [11].
Human β-defensins (hBD) are expressed in all human epithelial tissues [12] as one of
the products of phagocytic leucocytes, especially at the site of microbial colonisation
[13]. Both hBD1 and hBD2 genes are also expressed in human trachea and lung and are
believed to contribute to antimicrobial defence in the respiratory tract [14]. Since M.
tb inhabit lungs and certain leucocytes where defensins are produced, there is a need
to determine the levels of human defensin in the local environments (monocytes and
sputum), where M. tb normally infect.
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2. Materials and Methods
2.1. Study participants
This is a case-control study that involved the recruitment of 90 participants aged
between 15 and 64 years. After obtaining a written informed consent for this study, the
participants were divided into three groups that comprised of 30 multi-drug-resistant
TB (MDR-TB) patients, 30 drug-sensitive TB patients (DS-TB), and 30 non-TB, appar-
ently healthy, individuals as controls. The MDR-TB patients were diagnosed as being
infected with isoniazid and rifampicin-resistant strains of M. tb with the aid of their
clinical history, chest X-ray and GENE Xpert® test. After which they were admitted
into the MDR-TB centre, University College Hospital (UCH) Ibadan, Nigeria for anti-
TB treatment. As for the DS-TB patients, they were recruited from the Medicine Out-
patient Clinic at UCH, Ibadan, Nigeria, by a Consultant Chest Physician after laboratory
tests and chest X-rays were performed and from the clinical history presented. The
study protocol was reviewed and approved by the University of Ibadan/University
College Hospital Joint Institutional Research Ethics Committee.
Three millilitres (3 ml) of blood was drawn from the antecubital vein of each par-
ticipant into lithium heparin tube and mixed with 3ml of Phosphate Buffered Saline
(PBS). Lymphoprep (6ml) carefully layered on it and was at 600g for 15 mins to obtain
mononuclear cells above the mixture of polymorphonuclear cells and red blood cells.
Mononuclear cells obtained were washed, resuspended in Ringers solution, counted
and adjusted to 0.5 x 106 cells/ml. Mononuclear cell lysate was obtained by freeze
thaw method. Cell suspension was frozen for 15 mins at –20∘C and thawed at 4∘C for
30 mins. This procedure of freezing (–20∘C, 15 mins) and thawing (4∘C, 30 mins) was
repeated to make three cycles. Microscopic examination confirmed complete disrup-
tion of mononuclear cells. Lysate was stored at –20∘C until analysis.
Early-morning sputum samples were collected into sterile bottles to avoid contam-
ination. Sputum samples were diluted in Phosphate Buffer Saline (PBS) in a ratio 1:1
dilution factor. The mixture was centrifuged and the clear supernatant was collected
and stored for analysis at –20ºC.
Enzyme-linked Immunosorbent Assay (ELISA) method was used for the determina-
tion of mononuclear cell lysate and sputum concentrations of hBD 1 as specified by kit
manufacturer (Elabscience Biotechnology Co., Ltd, P.R.C). Student t-test was used to
compare two mean values; p-value less than 0.05 was considered significant.
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3. Results
As shown in Table 1, the mean levels of mononuclear cell lysate and sputum hBD1
in control, D0and M0 were compared in Table 1. The mean levels of lysate and sputum
hBD1 were not significantly different in D0when compared with the controls. The mean
levels of WBC lysate and sputum hBD1 were significantly higher in M0 compared with
D0 or control. However, the mean concentration of sputum hBD1 in M0 was higher than
the level in the lysate. The reverse was the case in other groups.
T 1: Mean levels of hBD 1 in mononuclear cell lysate and sputum hBD1 levels in controls, D0 and M0 at
diagnosis.
Variables Control (n = 30) D0 (n = 30) M0 (n = 30) F
WBC Lysate hBD1(pg/ml) 57.08 ± 12.71 57.58 ± 13.75 70.71 ± 21.27#+ 3.898
Sputum hBD1(pg/ml) 19.1 ± 4.7 35.5 ± 30.7 171.4 ± 210.4#+ 13.561#
#Significantly different when compared with controls,
#Significantly different when compared with controls,
+Significantly different when compared with D0
4. Discussion
Defensins, especially β-defensins, are known as endogenous antibiotics [15] that are
involved in antimycobacterial defence in the local environment, especially during the
inflammation and colonisation phase of mycobacterial infection [13]. Yet, studies on
the levels of hBD 1 in the lysate and sputum in TB patients is lacking, though reported
in the fluids of patients having other conditions apart from TB [16–18].
Our finding of increased levels of sputum and lysate hBD1 in M0 compared with D0
and control might be due to chronic nature of M. tb infection in the M0 group, which
would have led to increased recruitment and activation of immune cells (macrophages
and DCs), pro-inflammatory cytokines (TNF-α, IFN-γ, IL-1β and IL-6) and chemoat-
tractant. Secretion of pro-inflammatory cytokines, especially TNF-α, is a contributory
factor to increased inflammation in situ. This is further exacerbated by the consistent
replication and imminent necrotic activity of the M. tb within the macrophage leading
to increased leucocyte activation. This increased activation consequently cause pro-
duction of large amount of hBD1 from the epithelial cells in M0 with a view to inhibiting
the mycobacterial growth in the alveolar macrophages and defending other alveolar
cells from being infected.
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Non-significant differences observed when the mean levels of lysate and sputum
hBD1 in D0 were compared with the control could be attributed to the early or non-
severe phase of the M. tb infection in the patients. There is supporting evidence from
the studies conducted by Ertugrul et al [19] and Kaltsa et al [20], which reported higher
levels of hBD1 in chronic periodontitis patients comparedwith patients having gingivitis
and elevated levels of hBD1 in patients with cirrhosis when compared with hepatitis
patients and control.
One of the sites of β-defensins production is the epithelial cells of the lungs where
it acts as defence to mycobacterial infection and furthermore inhibits mycobacterial
growth. Defensins also act as chemoattractant to antigen specific T-cells and immature
macrophages with the aid of IL-2 and IFN-γ that inducemacrophage activation towards
the development of a microbicidal granuloma via host-specific cell-mediated immune
response to the end of halting the replication and spread of the infection to other parts
of the body. In an earlier study, Schwander et al. [21] reported high number of poly-
morphonuclear (PMN) cells and immature macrophages in BAL fluids from the lungs of
TB patients. Thus, the observed elevated levels of sputum hBD1 in M0compared with
D0 and controls could indicate that there is heightened production of hBD1 in the lungs
of M0 that probably resulted in high level of sputum hBD1 as observed by this study.
hBD1 is mainly expressed by epithelial cells, tissues and salivary glands, especially in
the local environment of the infection, which is in the epithelial of the lungs. This could
also account for higher level of sputum hBD1 compared with monocyte lysate hBD1.
5. Conclusion
1. Since the levels sputum and lysate hBD1 were higher in TB patients than normal
individuals, it shows that hBD1 might be involved in combating TB and may be
used as a therapeutic target for treating TB.
2. There is an association between and TB severity and hBD1.
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